---

---

entities : Takeda pharmaceutical company limited    exchanges : Nyse   

save search

---

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-04-23 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| Email alert Add to watchlist
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| Email alert Add to watchlist
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| Email alert Add to watchlist
granted approval cancer treatment for

---

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| 0.15% | O: -0.11% H: 0.0% C: 0.0%
NBIX | News M | $140.11 4.83% 4.6% 1.6M |

Health Technology

| 4.81% | O: 5.49% H: 2.84% C: -0.65%
nbi-1065 positive for

---

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Published: 2024-04-22 (Crawled : 09:00) - prnewswire.com
SMFNF | News | $55.76 -1.2% 59 |

Finance

| -0.36% | O: -0.16% H: 3.14% C: 0.04%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -0.11% | O: 0.63% H: 0.0% C: -0.31%
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| 1.33% | O: 0.8% H: 0.75% C: 0.38%
drug company for agreement

---

Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| 1.75% | O: 0.42% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| 4.79% | O: 0.82% H: 0.0% C: 0.0%
MIRM | $24.4 0.95% 0.94% 420K |

Health Technology

| 3.61% | O: -0.68% H: 2.52% C: 1.71%
report million reach treatment market

---

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| 1.75% | O: 0.0% H: 0.0% C: 0.0%
entyvio fda disease active for therapy

---

Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors
Published: 2024-04-15 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -0.67% | O: -1.19% H: 0.26% C: -0.98%
company

---

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -5.44% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

---

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -8.1% | O: -0.07% H: 0.0% C: -0.96%
iclusig fda drug takeda approval application

---

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -8.1% | O: -0.07% H: 0.0% C: -0.96%
CNTG | $0.504 7.21% 6.73% 72K |

Commercial Services

| -31.43% | O: 1.43% H: 1.41% C: -1.41%
partnership genetic takeda disorders

---

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -6.69% | O: 0.21% H: 0.97% C: 0.7%
NVS | News | $97.28 2.27% 0.31% 3.7M |

Health Technology

| -0.87% | O: 0.05% H: 0.14% C: -0.93%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -6.98% | O: -1.58% H: 0.0% C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M |

Health Technology

| -1.98% | O: -0.7% H: 0.73% C: -0.16%
ABBV | News | $169.54 0.98% -0.91% 4.1M |

Health Technology

| -5.97% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -1.53% | O: -0.02% H: 0.0% C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K |

Health Technology

| -5.39% | O: -0.27% H: 1.26% C: 0.84%
AMGN | News | $273.69 0.66% 0.65% 2.5M |

Health Technology

| 0.74% | O: 0.2% H: 1.14% C: -1.18%
antibody therapeutics market

---

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -6.89% | O: 0.21% H: 0.17% C: 0.14%
tak-079 positive topline potential results study

---

Alexandria Real Estate Equities, Inc. Announces Significant Early Renewal and 10-Year Lease Extension With Longstanding Credit Tenant Takeda at the Alexandria Center at Kendall Square Mega Campus in Cambridge
Published: 2024-03-04 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -8.1% | O: -0.69% H: 0.35% C: 0.14%
ARE | News A | $119.49 0.78% 0.0% 1.2M |

Finance

| -3.85% | O: -0.01% H: 1.98% C: 1.41%
extension

---

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -9.66% | O: 0.0% H: 0.47% C: 0.2%
vaccine dengue tak-003 qdenga

---

Plasma Therapy Global Market Report 2024 - Projected Compound Annual Growth Rate of 12.5%, with Market Set to Reach $0.88 Billion in 2028
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -9.23% | O: -0.2% H: 0.14% C: -0.48%
BAX | $41.02 1.54% 0.0% 2.6M |

Health Technology

| -2.87% | O: -0.38% H: 0.14% C: -0.14%
KMDA | $5.1 -0.99% 5.3K |

Health Technology

| -13.64% | O: 2.0% H: 2.28% C: 1.63%
ADMA 4 | $6.535 5.4% 5.13% 2.7M |

Health Technology

| 26.25% | O: 0.19% H: 2.5% C: 1.35%
report reach global set therapy growth market

---

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630 |

Health Technology

| -8.95% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -1.52% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | News | $138.73 -4.19% 3.7K |

Health Technology

| 10.47% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | News | $95.11 6.88% 490 |

Health Technology

| -5.82% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $64.93 -4.38% 6.2K |

Manufacturing

| 28.21% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -14.66% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -9.23% | O: -0.2% H: 0.14% C: -0.48%
NVS | News | $97.28 2.27% 0.31% 3.7M |

Health Technology

| -5.15% | O: -0.06% H: 0.46% C: 0.29%
GSK | News | $41.24 1.6% 0.0% 2.3M |

Health Technology

| -1.67% | O: -0.69% H: 1.42% C: 1.22%
LLY | News | $745.69 1.96% -0.16% 2M |

Health Technology

| -0.03% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.99 -0.31% 0.0% 9.1M |

Health Technology

| -3.77% | O: -0.65% H: 1.63% C: 1.48%
ABBV | News | $169.54 0.98% -0.91% 4.1M |

Health Technology

| -3.85% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| 1.19% | O: 1.67% H: 0.0% C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M |

Health Technology

| 8.85% | O: -2.81% H: 2.08% C: 1.38%
AMGN | News | $273.69 0.66% 0.65% 2.5M |

Health Technology

| -3.5% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

---

Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
Published: 2024-02-21 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -9.72% | O: -0.88% H: 0.34% C: 0.34%
entyvio disease biosimilar

---

Albumin Market to Reach $9.9 billion, Globally, by 2032 at 6.2% CAGR: Allied Market Research
Published: 2024-02-15 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130 |

Communications

| -0.53% | O: 3.61% H: 0.0% C: -0.13%
TMO | News | $574.59 4.78% -1.12% 2.5M |

Health Technology

| 4.8% | O: -0.18% H: 1.09% C: 0.24%
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -7.98% | O: -0.83% H: 0.38% C: 0.0%
reach research market

---

Protein Inhibitors Global Market Report 2024 - A $125 Billion Market in 2028, Registering Compound Annual Growth of 9%
Published: 2024-02-14 (Crawled : 02:00) - prnewswire.com
LZAGF | $541.144 -19.1% 24 |

Health Technology

| 11.76% | O: 3.14% H: 1.92% C: 1.92%
GLAXF | News | $20.305 -14.18% 630 |

Health Technology

| -6.95% | O: -2.14% H: 0.0% C: -0.63%
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| 1.37% | O: -2.71% H: 0.0% C: 0.0%
AZNCF | News | $138.73 -4.19% 3.7K |

Health Technology

| 13.6% | O: 0.87% H: 0.21% C: -2.23%
LZAGY | $55.69 0.02% 29K |

Professional, Scientific, and T...

| 15.95% | O: 4.07% H: 1.53% C: 1.45%
TMO | News | $574.59 4.78% -1.12% 2.5M |

Health Technology

| 6.68% | O: 0.56% H: 1.3% C: 1.22%
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -6.69% | O: 0.42% H: 1.04% C: 0.97%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -5.16% | O: -0.91% H: 0.0% C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M |

Health Technology

| -0.36% | O: 0.89% H: 0.41% C: 0.1%
LLY | News | $745.69 1.96% -0.16% 2M |

Health Technology

| 0.37% | O: 0.38% H: 2.44% C: 1.54%
BAX | $41.02 1.54% 0.0% 2.6M |

Health Technology

| 3.53% | O: 0.33% H: 0.63% C: -0.28%
ABBV | News | $169.54 0.98% -0.91% 4.1M |

Health Technology

| -2.82% | O: -0.73% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -4.43% | O: -0.83% H: 0.66% C: 0.38%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| 3.29% | O: -1.1% H: 0.0% C: 0.0%
GLPG | News | $29.47 1.38% 1.36% 120K |

Health Technology

| -24.6% | O: -1.72% H: 1.8% C: 1.59%
BIIB | $193.18 -0.48% -0.48% 1.4M |

Health Technology

| -14.77% | O: 0.16% H: 0.43% C: -2.76%
AZN | News | $70.85 1.03% 1.02% 5.6M |

Health Technology

| 16.09% | O: 0.28% H: 0.93% C: 0.75%
AMGN | News | $273.69 0.66% 0.65% 2.5M |

Health Technology

| -5.83% | O: -0.21% H: 0.34% C: 0.07%
report global protein growth market

---

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -6.5% | O: 0.14% H: 0.35% C: 0.07%
XNCR | $18.35 0.77% 0.76% 480K |

Health Technology

| -10.43% | O: -3.56% H: 2.91% C: -3.34%
MOR | News | $18.04 0.45% 0.44% 180K |

Health Technology

| 4.1% | O: -0.4% H: 0.23% C: -0.46%
MGNX | $16.23 5.32% 5.05% 650K |

Health Technology

| -9.43% | O: -5.25% H: 2.94% C: 2.18%
INCY | $51.62 -0.58% -0.58% 2.5M |

Health Technology

| -10.7% | O: 3.8% H: 1.1% C: -1.17%
financial

---

Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630 |

Health Technology

| -4.81% | O: 3.52% H: 0.0% C: -1.18%
AZNCF | News | $138.73 -4.19% 3.7K |

Health Technology

| 16.27% | O: 0.06% H: 2.34% C: 2.29%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -12.29% | O: 0.37% H: 0.74% C: 0.28%
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -6.5% | O: 0.14% H: 0.35% C: 0.07%
NVS | News | $97.28 2.27% 0.31% 3.7M |

Health Technology

| -3.23% | O: -0.34% H: 0.23% C: -1.13%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -4.5% | O: 0.7% H: 0.0% C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M |

Health Technology

| 0.41% | O: 1.22% H: 0.07% C: -0.43%
LLY | News | $745.69 1.96% -0.16% 2M |

Health Technology

| 1.14% | O: -0.96% H: 1.75% C: 1.75%
BMY | $48.99 -0.31% 0.0% 9.1M |

Health Technology

| -1.53% | O: -0.18% H: 0.48% C: -1.91%
ABBV | News | $169.54 0.98% -0.91% 4.1M |

Health Technology

| -2.04% | O: 0.8% H: 0.0% C: 0.0%
ZLAB | $15.13 0.93% 0.93% 470K |

Health Technology

| -16.97% | O: -1.15% H: 1.03% C: -1.5%
VRTX | $404.93 1.25% 1.43% 1.1M |

Health Technology

| -3.25% | O: -0.28% H: 0.49% C: -0.32%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| 3.23% | O: -0.06% H: 0.0% C: 0.0%
IPHA | $2.425 -7.02% 2.7K |

Health Technology

| -8.14% | O: -3.1% H: 1.2% C: -0.8%
INCY | $51.62 -0.58% -0.58% 2.5M |

Health Technology

| -10.7% | O: 3.8% H: 1.1% C: -1.17%
BIIB | $193.18 -0.48% -0.48% 1.4M |

Health Technology

| -21.07% | O: -3.72% H: 0.58% C: -3.82%
AZN | News | $70.85 1.03% 1.02% 5.6M |

Health Technology

| 15.37% | O: -0.26% H: 0.73% C: -0.36%
ARGX | $375.13 1.73% 1.7% 340K |

Health Technology

| -4.49% | O: -2.3% H: 1.65% C: 0.83%
AMGN | News | $273.69 0.66% 0.65% 2.5M |

Health Technology

| -7.1% | O: 0.06% H: 0.31% C: -1.4%
expansion growth market

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---